Bloomberg News

XenoPort Sinks as Spasticity Drug for MS Fails in Clinical Trial

May 20, 2013

XenoPort Inc. (XNPT:US), the maker of the drug Horizant for Restless Legs Syndrome, sank the most in almost three years after an experimental medicine failed to meet goals of a late-stage clinical trial.

XenoPort dropped 13 percent to $5.87 at 10:57 a.m. New York time after touching $5.03 for the biggest intraday decline since July 2010. The shares of the Santa Clara, California-based company had fallen 13 percent this year through May 17.

XenoPort is stopping development of arbaclofen placarbil, an experimental treatment for spasticity in multiple sclerosis patients, after the therapy didn’t help more than placebo, the company said in a statement today. Brian Abrahams, an analyst with Wells Fargo (WFC:US), had estimated sales of $77 million by 2017 for the drug.

“This is disappointing, given promising phase 2 data,” Abrahams wrote in a research note today. “The failure does remove a potential floor in valuation.”

To contact the reporter on this story: Meg Tirrell in New York at

To contact the editor responsible for this story: Reg Gale at

Silicon Valley State of Mind

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

Companies Mentioned

  • XNPT
    (XenoPort Inc)
    • $4.84 USD
    • -0.10
    • -2.07%
  • WFC
    (Wells Fargo & Co)
    • $50.85 USD
    • -0.01
    • -0.02%
Market data is delayed at least 15 minutes.
blog comments powered by Disqus